-
Product Insights
Celiac Disease – Drugs In Development, 2023
Global Markets Direct’s, ‘Celiac Disease - Drugs In Development, 2023’, provides an overview of the Celiac Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development for Celiac Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Enteritis – Drugs In Development, 2023
Global Markets Direct’s, ‘Enteritis - Drugs In Development, 2023’, provides an overview of the Enteritis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Enteritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Sector Analysis
Crohn’s Disease in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2032
Crohn’s Disease Market Report Overview The Crohn’s disease market size across the 8MM was $9.5 billion in 2022. The market will achieve a CAGR of more than 4% during 2022-2032 because of the approval and launch of 15 pipeline, generic, and biosimilar therapies. Crohn’s Disease Market Outlook, 2022-2032 ($ Billion) Buy the Full Report to Know More About the Crohn’s Disease Market Forecast Download a Free Report Sample The Crohn’s disease market research report offers a comprehensive insight into the...
-
Sector Analysis
Crohn’s Disease Epidemiology Analysis and Forecast to 2032
Crohn’s Disease Epidemiology Report Overview The number of the diagnosed prevalent cases of Crohn’s Disease (CD) in the 8MM was 1,626,752 in 2022. The number of diagnosed prevalent cases is further projected to grow by more than 4% during the forecast period at an AGR of 0.42% till 2032. Crohn’s disease (CD) is a type of inflammatory bowel disease (IBD) characterized by chronic inflammation of the gastrointestinal tract, which can lead to abdominal pain, severe diarrhea, fatigue, weight loss, and...
-
Product Insights
Celiac Disease Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Celiac Disease Clinical Trials Market Report Overview The Celiac Disease clinical trial market research report provides an overview of the Celiac Disease Clinical trials scenario. This report provides top-line data relating to the clinical trials on Celiac Disease and includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report also offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type....
-
Product Insights
Ulcerative Colitis Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Ulcerative Colitis Clinical Trials Market Report Overview The Ulcerative Colitis clinical trial market research report provides an overview of the Ulcerative Colitis Clinical trials scenario. This report provides top-line data relating to the clinical trials on Ulcerative Colitis and includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report also offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type....
-
Product Insights
Inflammatory Bowel Disease Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Inflammatory Bowel Disease Clinical Trials Market Overview A total of 4,343 inflammatory bowel disease clinical trials were conducted as of April 2023. The inflammatory bowel disease clinical trial market research report provides an overview of the inflammatory bowel disease clinical trials scenario. This report provides top-line data relating to the clinical trials on Inflammatory Bowel Disease. It also includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. Key Regions ·      Asia-Pacific ·      ...
-
Thematic Analysis
Digital Marketing Trends in Inflammatory Bowel Disease
Digital Marketing Trends in Inflammatory Bowel Disease Report Overview AbbVie’s Skyrizi.com achieved the highest total traffic across inflammatory bowel disease (IBD) patient sites in the US, with over 9.3 million visitors from March 2022 to February 2023. This was followed by AbbVie’s Rinvoq.com and Takeda’s Entyvio.com. The highest proportion of traffic originated from direct sources, followed by organic. Xeljanz.com was supported by the most paid search engine optimization (SEO) while Takeda spent on digital display advertising (DDA) for Entyvio.com. The digital marketing...
-
Sector Analysis
Ulcerative Colitis Market Size, Drug Analysis, Epidemiology, Disease Management, Pipeline Assessment, Unmet Needs and Forecast to 2031
Ulcerative Colitis Market Overview The ulcerative colitis (UC) market size across the 8MM was valued at $7.3 billion in 2021 and is expected to achieve a CAGR of more than 2% during 2021-2031. The symptoms of UC vary from person to person and may include diarrhea with blood or pus, passing blood with stool, abdominal pain & cramping, and tenesmus or urgency to defecate. UC can occur at any age, although most people are diagnosed in their mid-thirties. Men and...
-
Sector Analysis
Ulcerative Colitis Epidemiology Analysis and Forecast to 2031
Ulcerative Colitis Market Report Overview In the 8MM, there were 1,946,428 diagnosed prevalent cases of Ulcerative Colitis (UC) in 2021. The cases are expected to achieve an AGR of less than 1% during the period 2021-2031. Of the 8MM, Canada is expected to have the highest increase in the number of diagnosed prevalent cases of UC by 2031, and Italy will have the lowest increase in the number of diagnosed prevalent cases. Any change in the diagnosed prevalent cases of...